Maker of dubious $56K Alzheimer’s drug offers cognitive test no one can pass

Ars Technica » Scientific Method 2021-07-23

Summary:

After facing intense criticism, Biogen goes on defense, blames "misinformation."

Link:

https://arstechnica.com/?p=1782649

From feeds:

Cyberlaw » Ars Technica
Music and Digital Media » Ars Technica
Berkeley Law Library -- Reference & Research Services » Ars Technica » Scientific Method

Tags:

aduhelm

Authors:

Beth Mole

Date tagged:

07/23/2021, 17:00

Date published:

07/23/2021, 16:25